drugset / Trial / NCT00893971

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

NCT00893971

Phase 1 Completed 16 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety of a single dose of PT003 compared with single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as two separate single doses in healthy subjects.

Timeline

Start
2009-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 18 ug Inhaled
Subject PT003 Unknown 2.4 ug Inhaled
Subject PT003 Unknown 18 ug Inhaled
Subject PT005 Unknown 2.4 ug Inhaled

Indications

No indication recorded.